Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 359

1.

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

Derosa G.

Drugs. 2010 Oct 22;70(15):1945-61. doi: 10.2165/11538100-000000000-00000. Review.

PMID:
20883052
[PubMed - indexed for MEDLINE]
2.

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):166-74.

PMID:
17300592
[PubMed - indexed for MEDLINE]
3.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
[PubMed - indexed for MEDLINE]
4.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
[PubMed - indexed for MEDLINE]
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
6.

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.

PMID:
19349323
[PubMed - indexed for MEDLINE]
Free Article
7.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
[PubMed - indexed for MEDLINE]
8.

Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.

Papanas N, Katsiki N, Hatzitolios AI, Maltezos E.

Expert Opin Pharmacother. 2011 Jul;12(10):1457-61. doi: 10.1517/14656566.2011.568477.

PMID:
21651446
[PubMed - indexed for MEDLINE]
9.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
[PubMed - indexed for MEDLINE]
10.

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Diamant M, Heine RJ.

Drugs. 2003;63(13):1373-405. Review.

PMID:
12825962
[PubMed - indexed for MEDLINE]
11.

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237.

PMID:
17192117
[PubMed - indexed for MEDLINE]
12.

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M.

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):313-43. Epub 2006 Mar 22.

PMID:
16552630
[PubMed - indexed for MEDLINE]
13.

Rosiglitazone : a review of its use in type 2 diabetes mellitus.

Deeks ED, Keam SJ.

Drugs. 2007;67(18):2747-79. Review.

PMID:
18062722
[PubMed - indexed for MEDLINE]
14.

[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].

Rodríguez A, Reviriego J, Polavieja P, Mesa J.

Med Clin (Barc). 2008 Nov 29;131(19):721-30. Spanish.

PMID:
19091199
[PubMed - indexed for MEDLINE]
15.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
[PubMed - indexed for MEDLINE]
16.

Pioglitazone: a review of its use in type 2 diabetes mellitus.

Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM.

Drugs. 2006;66(1):85-109. Review. Erratum in: Drugs. 2006;66(3):340-1.

PMID:
16398569
[PubMed - indexed for MEDLINE]
17.

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Triplitt C, Cersosimo E, DeFronzo RA.

Vasc Health Risk Manag. 2010 Sep 7;6:671-90. Review.

PMID:
20859539
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.

Seufert J.

Curr Med Res Opin. 2006;22 Suppl 2:S39-48. Review.

PMID:
16914074
[PubMed - indexed for MEDLINE]
19.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Hermansen K, Mortensen LS.

Drug Saf. 2007;30(12):1127-42. Review.

PMID:
18035865
[PubMed - indexed for MEDLINE]
20.

Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.

Aguilar RB.

Clin Ther. 2011 Apr;33(4):408-24. doi: 10.1016/j.clinthera.2011.04.008. Review.

PMID:
21635988
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk